Related Experiment Video

Updated: Dec 22, 2025

Measurement of Factor V Activity in Human Plasma Using a Microplate Coagulation Assay
13:08

Measurement of Factor V Activity in Human Plasma Using a Microplate Coagulation Assay

Published on: September 9, 2012

19.3K

Single-Center Use of Prothrombin Complex Concentrate in Pediatric Patients

Takaharu Karube1, Courtney Andersen2, Joseph D Tobias3,4,5

  • 1Division of Pediatric Critical Care Medicine, Nationwide Children's Hospital, Columbus, Ohio, United States.

Journal of Pediatric Intensive Care
|May 1, 2020
PubMed

Insights

Four-factor prothrombin complex concentrate (4F-PCC) shows promise in managing bleeding in critically ill children. This study found 4F-PCC effectively reduced the international normalized ratio, suggesting improved hemostasis in pediatric patients.

Area of Science:

  • Pediatric Critical Care Medicine
  • Hematology
  • Pharmacology

Background:

  • Coagulation disturbances are common in critically ill children.
  • Four-factor prothrombin complex concentrate (4F-PCC) offers a potential alternative to fresh frozen plasma for managing coagulopathy.
  • Limited data exists on 4F-PCC use in critically ill pediatric populations.

Purpose of the Study:

  • To evaluate the efficacy of 4F-PCC in critically ill children.
  • To assess the impact of 4F-PCC on coagulopathy markers.
  • To explore the potential role of 4F-PCC in managing bleeding in pediatric trauma and surgical patients.

Main Methods:

  • Retrospective analysis of 24 critically ill pediatric patients who received 4F-PCC.
  • Primary indication: correction of coagulopathy and control of bleeding.
  • International normalized ratio (INR) was used as a surrogate marker for hemostasis.

Main Results:

  • 4F-PCC administration was associated with a decrease in the international normalized ratio.
  • The treatment was primarily used in trauma and surgical settings.
  • The study demonstrated a potential hemostatic effect of 4F-PCC.

Conclusions:

  • 4F-PCC effectively reduced INR in critically ill children, indicating a potential role in managing coagulopathy.
  • Further research is necessary to establish optimal dosing, indications, and safety profiles.
  • Larger prospective studies are warranted to confirm efficacy and identify adverse events in this patient group.

Keywords:
coagulopathypediatricsprothrombin complex concentrate

More Related Videos

Rapid Point-of-Care Assay of Enoxaparin Anticoagulant Efficacy in Whole Blood11:17

Rapid Point-of-Care Assay of Enoxaparin Anticoagulant Efficacy in Whole Blood

Published on: October 12, 2012

14.2K
Preparation and Pathogen Inactivation of Double Dose Buffy Coat Platelet Products using the INTERCEPT Blood System12:40

Preparation and Pathogen Inactivation of Double Dose Buffy Coat Platelet Products using the INTERCEPT Blood System

Published on: December 7, 2012

29.4K

Related Concept Videos

Pharmacokinetics in Pediatric Patients: Drug Distribution01:17

Pharmacokinetics in Pediatric Patients: Drug Distribution

Drug distribution in the pediatric population exhibits unique challenges and considerations due to the physiological differences between children, particularly neonates and infants, and adults. A crucial aspect of pediatric pharmacology is understanding how these differences impact the pharmacokinetics of various drugs, necessitating age-specific dosing strategies to ensure efficacy and safety.Neonates and infants have a higher total body water content, ~75%–90% of their body weight,...
194
Venous Thrombosis III: Interprofessional Care01:29

Venous Thrombosis III: Interprofessional Care

Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...
211
Pharmacokinetics in Pediatric Patients: Drug Metabolism01:24

Pharmacokinetics in Pediatric Patients: Drug Metabolism

In pediatric care, understanding the nuances of hepatic drug metabolism is crucial, as it significantly differs from that of adults. This divergence is primarily due to the developmental stage of drug-metabolizing enzymes, which affects how medications are processed in the body. In neonates, for instance, the activity of Phase I enzymes—critical for the initial breakdown of drugs—is markedly reduced, functioning at just 20–40% of the levels seen in adults. This reduction poses...
130
Pharmacokinetics in Pediatric Patients: Drug Excretion01:26

Pharmacokinetics in Pediatric Patients: Drug Excretion

In pediatric medicine, understanding the renal function and drug elimination nuances is crucial for administering safe and effective treatments. Newborns, in particular, display markedly slower renal functions than adults, profoundly affecting how drugs are cleared from their bodies. This slower drug clearance requires clinicians to extend the dosing intervals for many medications to prevent drug accumulation and toxicity while ensuring therapeutic efficacy.One key area where these adjustments...
148
EDTA: Auxiliary Complexing Reagents01:26

EDTA: Auxiliary Complexing Reagents

EDTA titrations are usually carried out in highly basic conditions, where the fully deprotonated form of EDTA, Y4−, actively complexes with the free metal ions in the solution. Several metal ions precipitate as hydrous oxide (hydroxides, oxides, or oxyhydroxides) under these conditions, lowering the concentration of free metal ions in the solution. For this reason, auxiliary complexing agents or ligands such as ammonia, tartrate, citrate, or triethanolamine are used in EDTA titrations to...
1.1K
Drug Dosing: Infants and Children01:29

Drug Dosing: Infants and Children

Pediatric patient dosages diverge from adults due to disparities in body surface area, total body water, and extracellular fluid per kilogram of body weight. The dosing regimen considers the variations in pharmacokinetics and pharmacology across distinct age groups, encompassing preterm newborns, infants, young children, older children, and adolescents. Calculation of pediatric patient doses is predicated on determining body surface area, which exhibits a superior correlation with the child's...
173